Ridgeback Biotherapeutics treatment to cure Ebola
An experimental treatment produced by Miami-based Ridgeback Biotherapeutics is helping turn Ebola into a treatable disease. The treatment, an antibody that prevents the virus from continuing to infect cells, is called mAb114. Ridgeback, a small company founded by Wendy Holman and funded by the Holman family, licensed the antibody from the National Institutes of Health in 2018. It is focusing on FDA approval and producing an Ebola treatment on a large scale.
This story also features expert opinions, business briefs and people in the news: Ridgeback Biotherapeutics; Wendy Holman; mAb114; Eduardo J. Padrón; Rolando Montoya; Telemundo Global Studios; Jorge Perez; El Espacio; Rubell Family Collection; Urbanica Management; Avalon Bonterra; Rodrigo Violante; Peter C. Anderson
Want to read the whole article?
Select from the following options:
* offer valid for new subscribers only